Cargando…

Safety and Immunogenicity of the Inactivated COVID-19 Vaccine Booster in People Living with HIV in China

Current knowledge regarding the long-term humoral response of people infected with human immunodeficiency virus to the third dose of inactivated coronavirus disease (COVID-19) vaccine is incomplete. As a result, concerns remain about the safety and efficacy of the vaccination. To improve our underst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Yunyun, Han, Xiaoxu, Cui, Xinyu, Wang, Peng, Wang, Xin, Liu, Hui, Wang, Yuqi, Zhu, Na, Li, Yanyan, Lin, Yingying, Li, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10302496/ https://www.ncbi.nlm.nih.gov/pubmed/37376408 http://dx.doi.org/10.3390/vaccines11061019

Ejemplares similares

Safety and Immunogenicity of Inactivated COVID-19 Vaccines Among People Living with HIV in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2022)

Effectiveness and Safety Analysis of PIs/r Based Dual Therapy in Treatment-Naïve, HIV/AIDS Patients: A Network Meta Analysis of Randomized Controlled Trials
por: Hui, Liu, et al.
Publicado: (2022)

Immunogenicity and Safety of BNT162b2 Homologous Booster Vaccination in People Living with HIV under Effective cART
por: Gianserra, Laura, et al.
Publicado: (2022)

Acceptance, safety and immunogenicity of a booster dose of inactivated SARS-CoV-2 vaccine in adults with tuberculosis
por: Zhan, Haoting, et al.
Publicado: (2023)

Immunogenicity and effectiveness of COVID-19 booster vaccination among people living with HIV: a systematic review and meta-analysis
por: Cheng, Meng-Qun, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Safety and Immunogenicity of Inactivated Bacillus subtilis Spores as a Heterologous Antibody Booster for COVID-19 Vaccines
por: Sung, Johnny Chun-Chau, et al.
Publicado: (2022)

Safety and immunogenicity of a heterologous booster with an RBD virus-like particle vaccine following two- or three-dose inactivated COVID-19 vaccine
por: Yong, Xiaolan, et al.
Publicado: (2023)

A nomogram for predicting paradoxical immune reconstitution inflammatory syndrome associated with cryptococcal meningitis among HIV-infected individuals in China
por: Han, Xiaoxu, et al.
Publicado: (2022)

Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
por: Feng, Yanmeng, et al.
Publicado: (2021)

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV
por: Cheng, Shu-Hsing, et al.
Publicado: (2022)

COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity
por: Liu, Ying, et al.
Publicado: (2021)

The safety and immunogenicity of a two-dose schedule of CoronaVac, and the immune persistence of vaccination for six months, in people living with HIV: A multicenter prospective cohort study
por: Wang, Yuxiao, et al.
Publicado: (2023)

Safety and immunogenicity of CoronaVac in people living with HIV: a prospective cohort study
por: Netto, Lucas C, et al.
Publicado: (2022)

Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine
por: Cao, Yunlong, et al.
Publicado: (2021)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

Immunogenicity and Safety of Beta-Adjuvanted Recombinant Booster Vaccine
por: Launay, Odile, et al.
Publicado: (2022)

Safety and immunogenicity following a homologous booster dose of CoronaVac in children and adolescents
por: Wang, Lei, et al.
Publicado: (2022)

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine
por: Kanokudom, Sitthichai, et al.
Publicado: (2022)

Immunogenicity of COVID-19 Vaccination in People Living with HIV: Progress and Challenges
por: Song, Jin-Wen, et al.
Publicado: (2023)

Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis
por: Kang, Liangyu, et al.
Publicado: (2022)

Safety and immunogenicity of booster dose in patients with chronic liver disease
por: Cossiga, V., et al.
Publicado: (2023)

Covid-19 vaccine immunogenicity in people living with HIV-1
por: Nault, Lauriane, et al.
Publicado: (2022)

Safety and immunogenicity of an inactivated whole cell tuberculosis vaccine booster in adults primed with BCG: A randomized, controlled trial of DAR-901
por: von Reyn, C. Fordham, et al.
Publicado: (2017)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Role of triglycerides as a predictor of autoimmune hepatitis with cirrhosis
por: Wang, Peng, et al.
Publicado: (2022)

Immunogenicity and Safety of a Booster Dose of Live Attenuated Varicella Vaccine, and Immune Persistence of a Primary Dose for Children Aged 2 to 6 Years
por: Zhang, Yukai, et al.
Publicado: (2022)

Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis
por: Staadegaard, Lisa, et al.
Publicado: (2022)

Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis
por: Zhao, Tianyu, et al.
Publicado: (2023)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Immune response and safety to inactivated COVID-19 vaccine: a comparison between people living with HIV and HIV-naive individuals
por: Zou, Shi, et al.
Publicado: (2022)

Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys
por: Zhou, Jun, et al.
Publicado: (2005)

Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies
por: Wang, Xun, et al.
Publicado: (2022)

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1
por: Levy, Itzchak, et al.
Publicado: (2021)

The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients
por: Yang, Lei, et al.
Publicado: (2023)

Protective effect of ursodeoxycholic acid on COVID-19 in patients with chronic liver disease
por: Li, Yanyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_o3jk79o63gnstu7lqvecn7vlm2